AIDS HEALTHCARE FOUNDATION

• Pharmacist Jay Holloway highlights single-tablet regimens and long-acting injectables like CABENUVA as key advancements improving HIV medication adherence and patient outcomes. • The PURPOSE trial, evaluating lenacapavir for PrEP, shows promise in providing more tools to meet diverse patient needs and preferences in HIV prevention. • Holloway emphasizes the importance of addressing health disparities and supporting the overall well-being of individuals living with HIV to improve medication adherence and outcomes. • Undetectable equals untransmissible (U=U) concept is crucial; individuals with undetectable viral loads cannot transmit HIV sexually, reducing stigma and promoting public health.

• Gilead Sciences will roll out Lenacapavir in 120 low-income countries via royalty-free licenses, offering a twice-yearly injectable for HIV prevention. • Clinical trials showed Lenacapavir's high efficacy in reducing HIV transmission, surpassing daily oral PrEP regimens, leading to early study halts for expedited approval. • Exclusion of middle- and high-income countries with high HIV rates, like Brazil and Mexico, has drawn criticism from advocacy groups. • UNAIDS welcomes Lenacapavir's expansion but urges broader access to ensure the medication reaches all who need it to combat the global HIV epidemic.